AI is not that smart

Author argues AI is being oversold and falls short of human intelligence, criticizing a narrowed commercial definition of AGI and emphasizing human senses, judgment and faith-based wisdom. Implication for portfolios: negligible near-term market impact, but persistent hype may skew sentiment and influence future policy or investment narratives rather than drive immediate valuation changes.

Analysis

Market pricing has baked an AGI-first narrative into a narrow cohort of hardware and model vendors; if corporate buyers pivot toward conservative, human-in-the-loop deployments instead of broad foundation-model rollouts, expect a 20–30% re-rating on the most leverageable names over 3–12 months as revenue growth and capex guidance come under scrutiny. The shift is not binary — narrow AI will continue to improve productivity — but the marginal dollar will move toward augmentation, explainability, and compliance rather than pure compute scale, changing where incremental spend accrues.

Winners from a prolonged ‘AI-is-not-AGI’ reality are companies that monetize human oversight and governance (cyber/compliance/software integrators), B2B services that embed curated domain expertise, and labor-intensive healthcare and education providers where regulation and trust limit automation. Losers are the high-valuation hardware and foundation-model vendors whose TAM assumptions depend on aggressive adoption: their downstream suppliers (memory, cooling, fab expansion projects) face second-order demand risk within 6–18 months if corporate ROI thresholds aren’t met.

Catalysts to watch: sequential capex guidance downgrades from top datacenter spenders (next 1–2 quarters), major enterprise pilot failure case studies hitting media (weeks–months), and policy/regulatory moves toward explainability and human-in-loop mandates (6–24 months). The primary tail risk that would unwind this view is a credible, measurable AGI or AGI-adjacent breakthrough — that event would re-rate the whole ecosystem instantly and is low-probability but high-impact.

Contrarian angle: consensus underestimates persistent value in human-centric platforms that resist full automation; investors who rotate from raw compute to firms that sell governance, staffing, and domain-specific augmentation capture steadier cash flows with lower binary risk. Positioning should be tactical into identifiable catalysts rather than a long-duration bet on AGI realization.

Key Decisions for Investors

• Pair trade (3–9 months): Short NVDA (or buy 3–6 month 5–10% OTM puts) vs long ACN — rationale: NVDA is exposed to discretionary datacenter GPU demand that could slip; ACN benefits from slower rollouts via increased systems integration spend. Risk/reward: NVDA downside capped by long-term secular GPU demand (tail AGI); ACN upside steady with lower binary risk.
• Long AMN (6–12 months): exposure to healthcare staffing and human-in-the-loop services where automation adoption is slow and margins re-rate upward as demand remains sticky. Risk/reward: lower volatility, secular cash flows; downside from unexpected reimbursement cuts or macro slowdown.
• Long cybersecurity/governance names (CRWD or ZS, 6–12 months): expected reallocation into explainability, monitoring and compliance tools if enterprises slow foundation-model deployments. Risk/reward: idiosyncratic execution risk but asymmetric upside if regulation raises switching costs for compliant vendors.
• Event hedge (0–3 months): Buy short-dated puts on a top AI hardware name sized as insurance (cost = <1–2% portfolio) to protect against near-term capex guidance shocks; accept premium drag if no shock occurs.